Literature DB >> 22929861

Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity.

Angela Ng1, Kristy K Brock, Michael B Sharpe, Joanne L Moseley, Tim Craig, David C Hodgson.   

Abstract

PURPOSE: Understanding the relationship between normal tissue dose and delayed radiation toxicity is an important component of developing more effective radiation therapy. Late outcome data are generally available only for patients who have undergone 2-dimensional (2D) treatment plans. The purpose of this study was to evaluate the accuracy of 3D normal tissue dosimetry derived from reconstructed 2D treatment plans in Hodgkin's lymphoma (HL) patients. METHODS AND MATERIALS: Three-dimensional lung, heart, and breast volumes were reconstructed from 2D planning radiographs for HL patients who received mediastinal radiation therapy. For each organ, a reference 3D organ was modified with patient-specific structural information, using deformable image processing software. Radiation therapy plans were reconstructed by applying treatment parameters obtained from patient records to the reconstructed 3D volumes. For each reconstructed organ mean dose (Dmean) and volumes covered by at least 5 Gy (V5) and 20 Gy (V20) were calculated. This process was performed for 15 patients who had both 2D and 3D planning data available to compare the reconstructed normal tissue doses with those derived from the primary CT planning data and also for 10 historically treated patients with only 2D imaging available.
RESULTS: For patients with 3D planning data, the normal tissue doses could be reconstructed accurately using 2D planning data. Median differences in Dmean between reconstructed and actual plans were 0.18 Gy (lungs), -0.15 Gy (heart), and 0.30 Gy (breasts). Median difference in V5 and V20 were less than 2% for each organ. Reconstructed 3D dosimetry was substantially higher in historical mantle-field treatments than contemporary involved-field mediastinal treatments: average Dmean values were 15.2 Gy vs 10.6 Gy (lungs), 27.0 Gy vs 14.3 Gy (heart), and 8.0 Gy vs 3.2 Gy (breasts).
CONCLUSIONS: Three-dimensional reconstruction of absorbed dose to organs at risk can be estimated accurately many years after exposure by using limited 2D data. Compared to contemporary involved-field treatments, normal tissue doses were significantly higher in historical mantle-field treatments. These methods build capacity to quantify the relationship between 3D normal tissue dose and observed late effects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22929861     DOI: 10.1016/j.ijrobp.2012.06.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation.

Authors:  Daniel Gasic; Per Munck Af Rosenschöld; Ivan R Vogelius; Maja V Maraldo; Marianne C Aznar; Karsten Nysom; Thomas Björk-Eriksson; Søren M Bentzen; Nils Patrik Brodin
Journal:  Radiother Oncol       Date:  2018-05-30       Impact factor: 6.280

2.  Automatic generation of three-dimensional dose reconstruction data for two-dimensional radiotherapy plans for historically treated patients.

Authors:  Ziyuan Wang; Marco Virgolin; Peter A N Bosman; Koen F Crama; Brian V Balgobind; Arjan Bel; Tanja Alderliesten
Journal:  J Med Imaging (Bellingham)       Date:  2020-02-03

3.  Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab.

Authors:  Christopher McLaughlin; Anthony Ricco; Raj Singh; Nitai Mukhopadhyay; Nevena Skoro; Selamawit Girma; Xiaoyan Deng; Shiyu Song
Journal:  Adv Radiat Oncol       Date:  2022-02-28

4.  Reducing Heart Dose with Protons and Cardiac Substructure Sparing for Mediastinal Lymphoma Treatment.

Authors:  Kekoa Taparra; Scott C Lester; W Scott Harmsen; Molly Petersen; Ryan K Funk; Miran J Blanchard; Phillip Young; Joerg Herrmann; Ashley Hunzeker; Heather Schultz; Cynthia McCollough; Alexandria Tasson; Shuai Leng; James A Martenson; Thomas J Whitaker; Eric Williamson; Nadia N Laack
Journal:  Int J Part Ther       Date:  2020-09-04

5.  A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials.

Authors:  Rachel Zhou; Angela Ng; Louis S Constine; Marilyn Stovall; Gregory T Armstrong; Joseph P Neglia; Debra L Friedman; Kara Kelly; Thomas J FitzGerald; David C Hodgson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-04       Impact factor: 7.038

6.  Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

Authors:  Nicola S Russell; Inge M Krul; Anna M van Eggermond; Berthe M P Aleman; Rosie Cooke; Susanne Kuiper; Steven D Allen; Matthew G Wallis; Damien Llanas; Ibrahima Diallo; Florent de Vathaire; Susan A Smith; Michael Hauptmann; Annegien Broeks; Anthony J Swerdlow; Flora E Van Leeuwen
Journal:  Clin Transl Radiat Oncol       Date:  2017-10-24

7.  Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol.

Authors:  Nicolas Waespe; Sven Strebel; Tiago Nava; Chakradhara Rao S Uppugunduri; Denis Marino; Veneranda Mattiello; Maria Otth; Fabienne Gumy-Pause; André O Von Bueren; Frederic Baleydier; Luzius Mader; Adrian Spoerri; Claudia E Kuehni; Marc Ansari
Journal:  BMJ Open       Date:  2022-01-24       Impact factor: 2.692

8.  Validation and Comparison of Radiograph-Based Organ Dose Reconstruction Approaches for Wilms Tumor Radiation Treatment Plans.

Authors:  Ziyuan Wang; Marco Virgolin; Brian V Balgobind; Irma W E M van Dijk; Susan A Smith; Rebecca M Howell; Matthew M Mille; Choonsik Lee; Choonik Lee; Cécile M Ronckers; Peter A N Bosman; Arjan Bel; Tanja Alderliesten
Journal:  Adv Radiat Oncol       Date:  2022-07-04

9.  Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation.

Authors:  John D Groarke; Sanjay Divakaran; Anju Nohria; Joseph H Killoran; Sharmila Dorbala; Ruth M Dunne; Jon Hainer; Viviany R Taqueti; Ron Blankstein; Harvey J Mamon; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2020-07-20       Impact factor: 5.952

10.  Current knowledge and future research directions in treatment-related second primary malignancies.

Authors:  Lindsay M Morton; Anthony J Swerdlow; Michael Schaapveld; Safaa Ramadan; David C Hodgson; John Radford; Flora E van Leeuwen
Journal:  EJC Suppl       Date:  2014-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.